DK170347B1 - Molekylært koordinationscomplex, fremgangsmåde til fremstilling heraf, anvendelse af complexet i et præparat og præparat indeholdende complexet - Google Patents

Molekylært koordinationscomplex, fremgangsmåde til fremstilling heraf, anvendelse af complexet i et præparat og præparat indeholdende complexet Download PDF

Info

Publication number: DK170347B1
Authority: DK; Denmark
Prior art keywords: cellulose; polymer; alcohol; carbon atoms; complex
Prior art date: 1979-12-19

Application number

DK527680A

Other languages

Danish (da)

English (en)

Other versions

DK527680A (da

Inventor

Stewart Thomas Leslie

Original Assignee

Euro Celtique Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-12-19

Filing date

1980-12-10

Publication date

1995-08-07

1980-12-10 Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa

1981-08-05 Publication of DK527680A publication Critical patent/DK527680A/da

1995-08-07 Application granted granted Critical

1995-08-07 Publication of DK170347B1 publication Critical patent/DK170347B1/da

Links

238000000034 method Methods 0.000 title claims description 22
150000004696 coordination complex Chemical class 0.000 title claims description 20
230000008569 process Effects 0.000 title claims description 16
238000002360 preparation method Methods 0.000 title description 13
229920000642 polymer Polymers 0.000 claims description 121
229920002678 cellulose Polymers 0.000 claims description 110
239000001913 cellulose Substances 0.000 claims description 108
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 56
239000000203 mixture Substances 0.000 claims description 52
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 36
239000002904 solvent Substances 0.000 claims description 33
125000004432 carbon atom Chemical group C* 0.000 claims description 29
GLDOVTGHNKAZLK-UHFFFAOYSA-N n-octadecyl alcohol Natural products CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 29
239000007787 solid Substances 0.000 claims description 25
229920013821 hydroxy alkyl cellulose Polymers 0.000 claims description 22
239000002798 polar solvent Substances 0.000 claims description 22
229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 18
229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 18
125000000217 alkyl group Chemical group 0.000 claims description 15
239000004480 active ingredient Substances 0.000 claims description 12
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 12
-1 myristy-1- Chemical group 0.000 claims description 11
BXWNKGSJHAJOGX-UHFFFAOYSA-N n-hexadecyl alcohol Natural products CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 11
238000013270 controlled release Methods 0.000 claims description 9
229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 8
239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 8
235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 8
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
125000001931 aliphatic group Chemical group 0.000 claims description 5
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
239000000155 melt Substances 0.000 claims description 5
229940082500 cetostearyl alcohol Drugs 0.000 claims description 4
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 4
239000003405 delayed action preparation Substances 0.000 claims description 3
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
150000002576 ketones Chemical class 0.000 claims description 2
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
239000002671 adjuvant Substances 0.000 claims 2
125000003158 alcohol group Chemical group 0.000 claims 2
239000000945 filler Substances 0.000 claims 2
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 47
235000019441 ethanol Nutrition 0.000 description 33
238000007614 solvation Methods 0.000 description 33
239000000243 solution Substances 0.000 description 26
239000011159 matrix material Substances 0.000 description 23
238000006243 chemical reaction Methods 0.000 description 22
239000000126 substance Substances 0.000 description 18
239000003826 tablet Substances 0.000 description 18
150000001875 compounds Chemical class 0.000 description 17
239000000306 component Substances 0.000 description 15
HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 14
239000003795 chemical substances by application Substances 0.000 description 13
229910052739 hydrogen Inorganic materials 0.000 description 13
239000001257 hydrogen Substances 0.000 description 13
239000013543 active substance Substances 0.000 description 12
230000000694 effects Effects 0.000 description 12
239000000499 gel Substances 0.000 description 11
239000002245 particle Substances 0.000 description 11
239000011148 porous material Substances 0.000 description 11
239000008187 granular material Substances 0.000 description 10
125000004435 hydrogen atom Chemical group [H]* 0.000 description 10
239000012453 solvate Substances 0.000 description 10
150000002191 fatty alcohols Chemical class 0.000 description 9
239000000047 product Substances 0.000 description 9
239000013522 chelant Substances 0.000 description 8
LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 8
239000000454 talc Substances 0.000 description 8
229910052623 talc Inorganic materials 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 7
229940043348 myristyl alcohol Drugs 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
239000002775 capsule Substances 0.000 description 6
239000003085 diluting agent Substances 0.000 description 6
238000001035 drying Methods 0.000 description 6
239000008101 lactose Substances 0.000 description 6
238000005259 measurement Methods 0.000 description 6
229920000609 methyl cellulose Polymers 0.000 description 6
239000001923 methylcellulose Substances 0.000 description 6
235000010981 methylcellulose Nutrition 0.000 description 6
229960000541 cetyl alcohol Drugs 0.000 description 5
150000004676 glycans Polymers 0.000 description 5
239000006187 pill Substances 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
229920003086 cellulose ether Polymers 0.000 description 4
230000008859 change Effects 0.000 description 4
230000007423 decrease Effects 0.000 description 4
238000009792 diffusion process Methods 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
230000003993 interaction Effects 0.000 description 4
239000000314 lubricant Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000002808 molecular sieve Substances 0.000 description 4
230000035699 permeability Effects 0.000 description 4
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 4
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
230000032683 aging Effects 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
230000035515 penetration Effects 0.000 description 3
229920001282 polysaccharide Polymers 0.000 description 3
239000005017 polysaccharide Substances 0.000 description 3
239000001103 potassium chloride Substances 0.000 description 3
235000011164 potassium chloride Nutrition 0.000 description 3
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
229960005205 prednisolone Drugs 0.000 description 3
230000008961 swelling Effects 0.000 description 3
238000009827 uniform distribution Methods 0.000 description 3
238000005303 weighing Methods 0.000 description 3
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 2
229920003043 Cellulose fiber Polymers 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
229960001138 acetylsalicylic acid Drugs 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
229920013820 alkyl cellulose Polymers 0.000 description 2
FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 2
229960003556 aminophylline Drugs 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000003125 aqueous solvent Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
125000004181 carboxyalkyl group Chemical group 0.000 description 2
229920003064 carboxyethyl cellulose Polymers 0.000 description 2
238000001246 colloidal dispersion Methods 0.000 description 2
230000008602 contraction Effects 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
239000003337 fertilizer Substances 0.000 description 2
229960003711 glyceryl trinitrate Drugs 0.000 description 2
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
150000004804 polysaccharides Polymers 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
229920005613 synthetic organic polymer Polymers 0.000 description 2
230000009974 thixotropic effect Effects 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
229940125758 compound 15 Drugs 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000005260 corrosion Methods 0.000 description 1
230000007797 corrosion Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000004880 explosion Methods 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
238000001879 gelation Methods 0.000 description 1
125000004395 glucoside group Chemical group 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
125000001183 hydrocarbyl group Chemical group 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
125000002768 hydroxyalkyl group Chemical group 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
229920005615 natural polymer Polymers 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229920000620 organic polymer Polymers 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
239000000575 pesticide Substances 0.000 description 1
239000005426 pharmaceutical component Substances 0.000 description 1
230000000243 photosynthetic effect Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000000518 rheometry Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
239000012085 test solution Substances 0.000 description 1
238000012546 transfer Methods 0.000 description 1
229940099259 vaseline Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B11/00—Preparation of cellulose ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/05—Alcohols; Metal alcoholates

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Polymers & Plastics (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Materials Engineering (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Medicinal Preparation (AREA)
Processes Of Treating Macromolecular Substances (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Compositions Of Macromolecular Compounds (AREA)
Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)

DK527680A 1979-12-19 1980-12-10 Molekylært koordinationscomplex, fremgangsmåde til fremstilling heraf, anvendelse af complexet i et præparat og præparat indeholdende complexet DK170347B1 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
IE248179		1979-12-19
IE248079		1979-12-19
IE2480/79A IE49324B1 (en)	1979-12-19	1979-12-19	Controlled release compositions
IE248179		1979-12-19

Publications (2)

Publication Number	Publication Date
DK527680A DK527680A (da)	1981-08-05
DK170347B1 true DK170347B1 (da)	1995-08-07

Family

ID=26319271

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK527680A DK170347B1 (da)	1979-12-19	1980-12-10	Molekylært koordinationscomplex, fremgangsmåde til fremstilling heraf, anvendelse af complexet i et præparat og præparat indeholdende complexet

Country Status (27)

Country	Link
US (1)	US4366310A (cs)
EP (1)	EP0032004B1 (cs)
JP (1)	JPS5698201A (cs)
AU (1)	AU541246B2 (cs)
BE (1)	BE886711A (cs)
CA (1)	CA1168230A (cs)
CS (1)	CS228142B2 (cs)
DE (1)	DE3048028A1 (cs)
DK (1)	DK170347B1 (cs)
EG (1)	EG14984A (cs)
ES (1)	ES497906A0 (cs)
FI (1)	FI66623C (cs)
FR (1)	FR2474507B1 (cs)
GB (1)	GB2067569B (cs)
GR (1)	GR72265B (cs)
HU (1)	HU188085B (cs)
IE (1)	IE49324B1 (cs)
IL (1)	IL61677A (cs)
MX (1)	MX158088A (cs)
NL (1)	NL187401C (cs)
NO (1)	NO152846C (cs)
NZ (1)	NZ195793A (cs)
PL (1)	PL133079B1 (cs)
PT (1)	PT72214B (cs)
SU (1)	SU1178326A3 (cs)
YU (1)	YU40957B (cs)
ZA (1)	ZA807716B (cs)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1211266A (en) *	1982-11-12	1986-09-16	Alfred E. Lauchenauer	Shaped semi-solid articles
DE3306621A1 (de) *	1983-02-25	1984-08-30	Hoechst Ag, 6230 Frankfurt	Verfahren zur herstellung von celluloseethern mit einem dimethoxyethan enthaltenden dispergierhilfsmittel
GB8514665D0 (en) *	1985-06-11	1985-07-10	Eroceltique Sa	Oral pharmaceutical composition
GB8613688D0 (en) *	1986-06-05	1986-07-09	Euro Celtique Sa	Pharmaceutical composition
ES2058111T3 (es) *	1986-06-10	1994-11-01	Euro Celtique Sa	Composicion de liberacion controlada de dihidrocodeina.
GB8626098D0 (en) *	1986-10-31	1986-12-03	Euro Celtique Sa	Controlled release hydromorphone composition
US5055300A (en) *	1988-06-17	1991-10-08	Basic Bio Systems, Inc.	Time release protein
US5023080A (en) *	1988-06-17	1991-06-11	Basic Bio Systems, Inc.	Time release protein
US5079005A (en) *	1988-06-17	1992-01-07	Gupta Kashmiri L	Time release protein
US5476668A (en) *	1990-08-24	1995-12-19	Shin-Etsu Chemical Co., Ltd.	Base for film-coating pharmaceuticals and method for preparing same
NZ260408A (en)	1993-05-10	1996-05-28	Euro Celtique Sa	Controlled release preparation comprising tramadol
US5891471A (en) *	1993-11-23	1999-04-06	Euro-Celtique, S.A.	Pharmaceutical multiparticulates
KR100354702B1 (ko) *	1993-11-23	2002-12-28	유로-셀티크 소시에떼 아노뉨	약학조성물의제조방법및서방형조성물
US5843480A (en) *	1994-03-14	1998-12-01	Euro-Celtique, S.A.	Controlled release diamorphine formulation
GB9422154D0 (en)	1994-11-03	1994-12-21	Euro Celtique Sa	Pharmaceutical compositions and method of producing the same
US5965161A (en)	1994-11-04	1999-10-12	Euro-Celtique, S.A.	Extruded multi-particulates
AU8532798A (en) *	1997-06-13	1998-12-30	Roland Bodmeier	Compounds which delay the release of active substances
DK1685839T3 (da)	1997-12-22	2013-06-24	Euro Celtique Sa	Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist
AU776666B2 (en)	2000-02-08	2004-09-16	Euro-Celtique S.A.	Tamper-resistant oral opioid agonist formulations
CN1525851A (zh)	2001-05-11	2004-09-01	��ҩ��޹�˾	抗滥用阿片样物质控释剂型
US7943173B2 (en)	2001-07-18	2011-05-17	Purdue Pharma L.P.	Pharmaceutical combinations of oxycodone and naloxone
WO2003013525A1 (en)	2001-08-06	2003-02-20	Euro-Celtique S.A.	Opioid agonist formulations with releasable and sequestered antagonist
US20030068375A1 (en)	2001-08-06	2003-04-10	Curtis Wright	Pharmaceutical formulation containing gelling agent
US20030044458A1 (en)	2001-08-06	2003-03-06	Curtis Wright	Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030157168A1 (en)	2001-08-06	2003-08-21	Christopher Breder	Sequestered antagonist formulations
CA2478515C (en)	2002-04-05	2010-09-28	Purdue Pharma	Pharmaceutical preparation containing oxycodone and naloxone
DK1551372T3 (en)	2002-09-20	2018-07-23	Alpharma Pharmaceuticals Llc	SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
US20040202717A1 (en)	2003-04-08	2004-10-14	Mehta Atul M.	Abuse-resistant oral dosage forms and method of use thereof
TWI347201B (en)	2003-04-21	2011-08-21	Euro Celtique Sa	Pharmaceutical products,uses thereof and methods for preparing the same
EP1604666A1 (en)	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1765292B1 (en)	2004-06-12	2017-10-04	Collegium Pharmaceutical, Inc.	Abuse-deterrent drug formulations
EP1702558A1 (en)	2005-02-28	2006-09-20	Euro-Celtique S.A.	Method and device for the assessment of bowel function
KR101486228B1 (ko)	2006-06-19	2015-01-26	알파마 파머슈티컬스 엘엘씨	약제학적 조성물
EP1897543A1 (en)	2006-08-30	2008-03-12	Euro-Celtique S.A.	Buprenorphine- wafer for drug substitution therapy
US8623418B2 (en)	2007-12-17	2014-01-07	Alpharma Pharmaceuticals Llc	Pharmaceutical composition
JP2010159364A (ja) *	2009-01-09	2010-07-22	Kyoto Univ	セルロースの高温での着色を抑制する方法
WO2010103039A1 (en)	2009-03-10	2010-09-16	Euro-Celtique S.A.	Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US10668060B2 (en)	2009-12-10	2020-06-02	Collegium Pharmaceutical, Inc.	Tamper-resistant pharmaceutical compositions of opioids and other drugs
WO2011141490A1 (en)	2010-05-10	2011-11-17	Euro-Celtique S.A.	Combination of active loaded granules with additional actives
NZ603173A (en)	2010-05-10	2014-10-31	Euro Celtique Sa	Manufacturing of active-free granules and tablets comprising the same
KR20130030260A (ko)	2010-05-10	2013-03-26	유로-셀티큐 에스.에이.	히드로모르폰 및 날록손을 포함하는 제약 조성물
EP2826467B1 (en)	2010-12-22	2017-08-02	Purdue Pharma L.P.	Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en)	2010-12-23	2022-10-24	Purdue Pharma Lp	Tamper resistant solid oral dosage forms
CN105120846B (zh)	2013-02-05	2019-10-18	普渡制药公司	抗篡改的药物制剂
US10751287B2 (en)	2013-03-15	2020-08-25	Purdue Pharma L.P.	Tamper resistant pharmaceutical formulations
KR20180037074A (ko)	2013-07-23	2018-04-10	유로-셀티큐 에스.에이.	장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
EP3068397A1 (en)	2013-11-13	2016-09-21	Euro-Celtique S.A.	Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
WO2017222575A1 (en)	2016-06-23	2017-12-28	Collegium Pharmaceutical, Inc.	Process of making more stable abuse-deterrent oral formulations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4264766A (en) *	1877-09-19	1981-04-28	Hoffmann-La Roche Inc.	Immunological diagnostic reagents
US2921883A (en) *	1957-05-03	1960-01-19	Smith Kline French Lab	Novel coating material for medicaments
US3133863A (en) *	1961-03-10	1964-05-19	Strong Cobb Arner Inc	Sustained release therapeutic tablet compositions comprising organic solvent-gelled gums
US3146167A (en) *	1961-10-05	1964-08-25	Smith Kline French Lab	Method of preparing sustained release pellets and products thereof
GB1405088A (en) *	1971-06-03	1975-09-03	Mundipharma Ag	Slow release formulation
US3988482A (en) *	1971-08-27	1976-10-26	Toyo Hakka Kogyo Kabushiki Kaisha	Menthol glycoside, process for preparing the same and method for releasing menthol therefrom
US3818107A (en) *	1972-09-28	1974-06-18	Brook D	Chewing gum with sustained flavor release compositions
US3899439A (en) *	1973-03-12	1975-08-12	Hercules Inc	Method of preparing aqueous dispersions of hydroxypropyl cellulose
DE2644678A1 (de) *	1976-10-02	1978-04-06	Dynamit Nobel Ag	Verfahren zur herstellung funktionalisierter cellulosen
JPS54105223A (en) *	1977-12-29	1979-08-18	Yamanouchi Pharmaceut Co Ltd	Coating agent for solid medicine
US4259355A (en) *	1979-03-05	1981-03-31	International Flavors & Fragrances Inc.	Chewing gum containing flavor composition and flavor composition therefor
US4226849A (en) *	1979-06-14	1980-10-07	Forest Laboratories Inc.	Sustained release therapeutic compositions
US4259314A (en) *	1979-12-10	1981-03-31	Hans Lowey	Method and composition for the preparation of controlled long-acting pharmaceuticals

1979
- 1979-12-19 IE IE2480/79A patent/IE49324B1/en not_active IP Right Cessation
1980
- 1980-07-17 PT PT72214A patent/PT72214B/pt unknown
- 1980-12-08 NZ NZ195793A patent/NZ195793A/xx unknown
- 1980-12-09 ZA ZA00807716A patent/ZA807716B/xx unknown
- 1980-12-09 IL IL61677A patent/IL61677A/xx not_active IP Right Cessation
- 1980-12-09 GB GB8039449A patent/GB2067569B/en not_active Expired
- 1980-12-09 EP EP80304430A patent/EP0032004B1/en not_active Expired
- 1980-12-10 DK DK527680A patent/DK170347B1/da not_active IP Right Cessation
- 1980-12-10 FI FI803848A patent/FI66623C/fi not_active IP Right Cessation
- 1980-12-10 US US06/214,625 patent/US4366310A/en not_active Expired - Lifetime
- 1980-12-11 AU AU65298/80A patent/AU541246B2/en not_active Expired
- 1980-12-15 CA CA000366770A patent/CA1168230A/en not_active Expired
- 1980-12-16 HU HU803005A patent/HU188085B/hu unknown
- 1980-12-17 BE BE0/203205A patent/BE886711A/fr not_active IP Right Cessation
- 1980-12-17 NO NO803836A patent/NO152846C/no not_active IP Right Cessation
- 1980-12-18 FR FR8026928A patent/FR2474507B1/fr not_active Expired
- 1980-12-18 PL PL1980228573A patent/PL133079B1/pl unknown
- 1980-12-18 NL NLAANVRAGE8006891,A patent/NL187401C/xx not_active IP Right Cessation
- 1980-12-18 GR GR63716A patent/GR72265B/el unknown
- 1980-12-18 ES ES497906A patent/ES497906A0/es active Granted
- 1980-12-18 YU YU3210/80A patent/YU40957B/xx unknown
- 1980-12-18 JP JP17962980A patent/JPS5698201A/ja active Granted
- 1980-12-18 SU SU803221253A patent/SU1178326A3/ru active
- 1980-12-18 CS CS809008A patent/CS228142B2/cs unknown
- 1980-12-19 DE DE19803048028 patent/DE3048028A1/de not_active Ceased
- 1980-12-20 EG EG80785A patent/EG14984A/xx active
1981
- 1981-01-05 MX MX185453A patent/MX158088A/es unknown

Also Published As

Publication number	Publication date
PT72214A (en)	1980-08-01
FI803848L (fi)	1981-06-20
FR2474507A1 (fr)	1981-07-31
FI66623C (fi)	1984-11-12
HUT34891A (en)	1985-05-28
SU1178326A3 (ru)	1985-09-07
AU6529880A (en)	1981-06-25
US4366310A (en)	1982-12-28
PL133079B1 (en)	1985-05-31
NL187401C (nl)	1991-09-16
BE886711A (fr)	1981-06-17
NO803836L (no)	1981-06-22
EG14984A (en)	1986-06-30
IL61677A (en)	1984-10-31
GB2067569A (en)	1981-07-30
EP0032004A2 (en)	1981-07-15
AU541246B2 (en)	1985-01-03
JPH0225921B2 (cs)	1990-06-06
CS228142B2 (en)	1984-05-14
ZA807716B (en)	1981-12-30
PT72214B (en)	1981-11-02
IE49324B1 (en)	1985-09-18
EP0032004B1 (en)	1985-05-15
MX158088A (es)	1989-01-06
NZ195793A (en)	1982-09-14
EP0032004A3 (en)	1982-07-14
GB2067569B (en)	1983-09-01
JPS5698201A (en)	1981-08-07
NL187401B (nl)	1991-04-16
CA1168230A (en)	1984-05-29
NO152846C (no)	1985-11-27
ES8303489A1 (es)	1983-02-01
IE792480L (en)	1981-06-19
HU188085B (en)	1986-03-28
NL8006891A (nl)	1981-07-16
FI66623B (fi)	1984-07-31
ES497906A0 (es)	1983-02-01
IL61677A0 (en)	1981-01-30
PL228573A1 (cs)	1982-07-19
DE3048028A1 (de)	1981-09-10
YU40957B (en)	1986-08-31
FR2474507B1 (fr)	1986-12-26
GR72265B (cs)	1983-10-10
YU321080A (en)	1983-06-30
DK527680A (da)	1981-08-05
NO152846B (no)	1985-08-19

Legal Events

Date	Code	Title	Description
1995-08-07	B1	Patent granted (law 1993)
2000-12-27	PUP	Patent expired

Publication	Publication Date	Title
EP0032004B1 (en)	1985-05-15	Controlled release compositions
Lenaerts et al.	1991	Controlled release of theophylline from cross-linked amylose tablets
Dürig et al.	2019	Binders in wet granulation
KR102912737B1 (ko)	2026-01-15	Parp 억제제를 포함하는 약학 조성물
CA1079638A (en)	1980-06-17	Coated granules of polyacrylic alkali metal salts and method of producing same
CN104434805B (zh)	2017-09-29	一种替格瑞洛固体分散体及其制备方法
EP2349218A1 (de)	2011-08-03	Verfahren zur herstellung oraler darreichungsformen mit kontrollierter freisetzung
CN115887730A (zh)	2023-04-04	适用于水胶体敷贴的微球及其制备方法以及复合蛋白缓释水胶体敷贴
Gad et al.	2014	Design, formulation, and evaluation of Piroxicam niosomal gel
US3853988A (en)	1974-12-10	Sustained released pharmaceutical compositions
US4406883A (en)	1983-09-27	Controlled release suppositories consisting essentially of a linear polymer particularly, polyvinyl pyrrolidones
CN119857070B (zh)	2025-09-12	一种复方薄荷脑软膏制备方法
Kornblum	1969	Sustained‐action tablets prepared by employing a spray‐drying technique for granulation
CA1208556A (en)	1986-07-29	Process for time controlled release of active ingredients from active material containing pharmaceutical preparations
JP2638156B2 (ja)	1997-08-06	薬剤組成物
Ramesh	2017	Design and Evaluation of Single and Multi-unitÂ Sustained Release Dosage Forms of Captopril
CN103006568A (zh)	2013-04-03	非洛地平固态分散物及其制备方法
Ahmad et al.	2022	Development and Characterization of Hydrogel containing Finasteride
Pragya et al.	2014	Formulation and evaluation of mouth dissolving film of felodipine
CN105878215A (zh)	2016-08-24	一种稳定的孟鲁司特口腔速溶膜及其制备方法和用途
CN118384133A (zh)	2024-07-26	他达拉非口溶膜剂及其制备方法
Al-Tawil et al.	2026	Smart supramolecular eutectogels-based deep eutectic solvent for pH-and thermo-responsive transdermal delivery of anticancer curcumin
CN109276550A (zh)	2019-01-29	一种左炔诺孕酮片及其制备方法
CN114129573A (zh)	2022-03-04	一种稳定的包含炔雌醇和醋酸炔诺酮的药物组合物
MXPA04011796A (es)	2005-03-31	Unidades de dosificacion progestagenica.